Fig. 7: 4-MU inhibits glioma growth in vivo and, when combined with autophagy inhibitors, exerts synergistic effects on glioma cell viability, autophagy levels, and the cell cycle. | Cell Death & Disease

Fig. 7: 4-MU inhibits glioma growth in vivo and, when combined with autophagy inhibitors, exerts synergistic effects on glioma cell viability, autophagy levels, and the cell cycle.

From: Interfering with hyaluronic acid metabolism suppresses glioma cell proliferation by regulating autophagy

Fig. 7: 4-MU inhibits glioma growth in vivo and, when combined with autophagy inhibitors, exerts synergistic effects on glioma cell viability, autophagy levels, and the cell cycle.The alternative text for this image may have been generated using AI.

A Viability of U251 glioma cells cultured with 4-MU, followed by treatment with CQ (30 μmol/L) for 48 h. B Levels of the Ki67 protein in U251 glioma cells were detected using immunofluorescence staining after culture with 4-MU, followed by treatment with CQ (30 μmol/L) for 48 h. C Relative levels of the P62 and MAP1LC3B proteins in U251 glioma cells cultured with 4-MU, followed by treatment with CQ (30 μmol/L) for 48 h. Scale bar: 50 μm. D The cell cycle distribution was detected in U251 glioma cells using flow cytometry after culture with 4-MU, followed by treatment with CQ (30 μmol/L) for 48 h (green: G0-G1, yellow: S, and blue: G2-M). E Relative levels of the CCNB1 and CCND1 proteins in U251 glioma cells cultured with 4-MU, followed by treatment with CQ (30 μmol/L) for 48 h. F Representative images of IHC staining for Ki67 and HA in the orthotopic xenograft tumors from the control and 4-MU treatment groups. Scale bar: 50 μm. G–H Representative MRIs of orthotopic xenograft tumors and survival curves of the control and 4-MU treatment groups. P: P-value for the comparison of the control and 4-MU groups. The data are presented as the mean ± SD; *P < 0.05, **P < 0.01, and ***P < 0.001, ****P < 0.0001.

Back to article page